A Machine Learning Algorithm to Predict the Starting Dose of Daptomycin.

IF 4.6 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Clinical Pharmacokinetics Pub Date : 2024-08-01 Epub Date: 2024-07-31 DOI:10.1007/s40262-024-01405-z
Florence Rivals, Sylvain Goutelle, Cyrielle Codde, Romain Garreau, Laure Ponthier, Pierre Marquet, Tristan Ferry, Marc Labriffe, Alexandre Destere, Jean-Baptiste Woillard
{"title":"A Machine Learning Algorithm to Predict the Starting Dose of Daptomycin.","authors":"Florence Rivals, Sylvain Goutelle, Cyrielle Codde, Romain Garreau, Laure Ponthier, Pierre Marquet, Tristan Ferry, Marc Labriffe, Alexandre Destere, Jean-Baptiste Woillard","doi":"10.1007/s40262-024-01405-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>The dosage of daptomycin is usually based on body weight. However, it has been shown that this approach yields too high an exposure in obese patients. Pharmacokinetic and pharmacodynamic indexes (PK/PD) have been proposed for daptomycin's antibacterial effect (AUC/CMI >666) and toxicity (C0 > 24.3 mg/L). We previously developed machine learning (ML) algorithms to predict starting doses based on Monte Carlo simulations. We propose a new way to perform probability of target attainment based on an ML algorithm to predict the daptomycin starting dose.</p><p><strong>Methods: </strong>The Dvorchik model of daptomycin was implemented in the mrgsolve R package and 4950 pharmacokinetic profiles were simulated with doses ranging from 4 to 12 mg/kg. We trained and benchmarked four machine learning algorithms and selected the best to iteratively search for the optimal dose of daptomycin maximizing the event (AUC/CMI > 666 and C0 < 24.3 mg/L). The ML algorithm was evaluated in simulations and an external database of real patients in comparison with population pharmacokinetics.</p><p><strong>Results: </strong>The performance of the Xgboost algorithms developed to predict the event (ROC AUC) in the training and test set were 0.762 and 0.761, respectively. The most important prediction variables were dose, creatinine clearance, body weight and sex. In the external database of real patients, the starting dose administered based on the ML algorithm significantly improved the target attainment by 7.9% (p-value = 0.02929) in comparison with the dose administered based on body weight.</p><p><strong>Conclusion: </strong>The developed algorithm improved the target attainment for daptomycin in comparison with weight-based dosing. We built a Shiny app to calculate the optimal starting dose.</p>","PeriodicalId":10405,"journal":{"name":"Clinical Pharmacokinetics","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacokinetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40262-024-01405-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: The dosage of daptomycin is usually based on body weight. However, it has been shown that this approach yields too high an exposure in obese patients. Pharmacokinetic and pharmacodynamic indexes (PK/PD) have been proposed for daptomycin's antibacterial effect (AUC/CMI >666) and toxicity (C0 > 24.3 mg/L). We previously developed machine learning (ML) algorithms to predict starting doses based on Monte Carlo simulations. We propose a new way to perform probability of target attainment based on an ML algorithm to predict the daptomycin starting dose.

Methods: The Dvorchik model of daptomycin was implemented in the mrgsolve R package and 4950 pharmacokinetic profiles were simulated with doses ranging from 4 to 12 mg/kg. We trained and benchmarked four machine learning algorithms and selected the best to iteratively search for the optimal dose of daptomycin maximizing the event (AUC/CMI > 666 and C0 < 24.3 mg/L). The ML algorithm was evaluated in simulations and an external database of real patients in comparison with population pharmacokinetics.

Results: The performance of the Xgboost algorithms developed to predict the event (ROC AUC) in the training and test set were 0.762 and 0.761, respectively. The most important prediction variables were dose, creatinine clearance, body weight and sex. In the external database of real patients, the starting dose administered based on the ML algorithm significantly improved the target attainment by 7.9% (p-value = 0.02929) in comparison with the dose administered based on body weight.

Conclusion: The developed algorithm improved the target attainment for daptomycin in comparison with weight-based dosing. We built a Shiny app to calculate the optimal starting dose.

Abstract Image

预测达托霉素起始剂量的机器学习算法。
背景和目的:达托霉素的剂量通常以体重为基础。然而,事实证明这种方法在肥胖患者中产生的暴露量过大。有人针对达托霉素的抗菌效果(AUC/CMI >666)和毒性(C0 > 24.3 mg/L)提出了药代动力学和药效学指标(PK/PD)。我们之前开发了基于蒙特卡罗模拟的机器学习(ML)算法来预测起始剂量。我们提出了一种基于 ML 算法预测达托霉素起始剂量的达到目标概率的新方法:方法:我们在 mrgsolve R 软件包中实现了达托霉素的 Dvorchik 模型,并模拟了 4950 个药代动力学曲线,剂量从 4 毫克/千克到 12 毫克/千克不等。我们对四种机器学习算法进行了训练和基准测试,并选择了其中最好的一种算法来迭代搜索达托霉素的最佳剂量,以最大化事件(AUC/CMI > 666 和 C0 结果):开发的 Xgboost 算法在训练集和测试集中预测事件的性能(ROC AUC)分别为 0.762 和 0.761。最重要的预测变量是剂量、肌酐清除率、体重和性别。在外部真实患者数据库中,与基于体重的给药剂量相比,基于 ML 算法的起始给药剂量显著提高了 7.9%(p 值 = 0.02929):结论:与基于体重的剂量相比,所开发的算法提高了达托霉素的达标率。我们开发了一个 Shiny 应用程序来计算最佳起始剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.80
自引率
4.40%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics. Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信